skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

23 Total results for product and free and sample content found

Scrip

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

By Jessica Merrill 14 Nov 2022

Pfizer Lays Out Multi-Phase COVID-19 Vaccine Commercial Strategy

The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.

Topic Coronavirus Vaccines Sales Earnings

Pink Sheet

With Warp Speed Decisions Already Made, Transitioning To Biden Admin Should Be No Trouble, Slaoui Says

By Derrick Gingery 08 Dec 2020

Covid19 Biden Transition

As vaccines near availability, Moncef Slaoui says his full-time role at OWS may be ending. He has not met with the Biden Transition team, but notes that other Warp Speed officials have.

Topic Coronavirus Vaccines US Election 2020

Scrip

UK Grants First Worldwide Authorization For Pfizer/BioNTech COVID-19 Vaccine

By Andrew McConaghie 08 Dec 2020

Covid19 vaccine BioNTech

The UK's MHRA has granted an emergency authorization to the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.

Topic Coronavirus Vaccines

HBW Insight

UK Researchers Seek Commercial Partner For Nasal Spray Shown To 'Prevent' COVID-19

By Tom Gallen 29 Nov 2020

covid19 nasal spray R&D

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

Topic Coronavirus Research & Development Vaccines OTC Drugs

Scrip

Quick Listen: Scrip's Five Must-Know Things

By Ian Haydock 29 Nov 2020

Scrip August Podcast

Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things

Topic Coronavirus Research & Development Vaccines

Pink Sheet

Coronavirus Supply Chain Threats Demand Coordinated Industry Response

By Bowman Cox 27 Nov 2020

Emergency Agency Meeting

Just as they did during the heparin crisis a decade ago, pharmaceutical companies must coordinate on coronavirus, Rx-360 CEO says.

Topic Manufacturing Vaccines Coronavirus

Datamonitor Healthcare

Priority Populations For COVID-19 Vaccination: Global Timelines For Deployment

17 Nov 2020

COVID-19 Vaccine

As the COVID-19 pandemic continues, governments worldwide have pinned their hopes on returning to normality on the development of a vaccine. With multiple vaccines currently in late-stage trials, there is promise that a successful vaccine will soon be ready.

Topic Coronavirus Vaccines

Pink Sheet

Pfizer's COVID-19 Vaccine Will Miss US Election, Bourla Clarifies

By Joseph Haas 29 Oct 2020

Pfizer CEO Albert Bourla

EUA request for COVID-19 vaccine is unlikely before late November; the CEO’s frequent comments that the timetable isn’t politically motivated are unusual to say the least

Topic US Election 2020 Vaccines Coronavirus

Scrip

J&J Says It's Wait And See On COVID-19 Vaccine Delay Outlines Rosier Outlook for 2021

By Jessica Merrill 19 Oct 2020

Scrip Covid19 Vaccine J&J

It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.

Topic Coronavirus Vaccines Clinical Trials

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: